Rapport Therapeutics (NASDAQ:RAPP – Get Free Report)’s stock price dropped 4.2% during trading on Friday . The company traded as low as $23.71 and last traded at $23.79. Approximately 9,394 shares changed hands during trading, a decline of 95% from the average daily volume of 171,124 shares. The stock had previously closed at $24.83.
Analysts Set New Price Targets
A number of brokerages recently commented on RAPP. Jefferies Financial Group began coverage on Rapport Therapeutics in a research note on Tuesday, July 2nd. They set a “buy” rating and a $35.00 price objective for the company. Stifel Nicolaus initiated coverage on Rapport Therapeutics in a research note on Tuesday, July 2nd. They set a “buy” rating and a $35.00 price target for the company. Finally, TD Cowen began coverage on shares of Rapport Therapeutics in a research note on Tuesday, July 2nd. They set a “buy” rating for the company.
Check Out Our Latest Stock Report on Rapport Therapeutics
Rapport Therapeutics Stock Down 3.3 %
Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($1.02). On average, equities analysts forecast that Rapport Therapeutics will post -3.46 EPS for the current fiscal year.
Hedge Funds Weigh In On Rapport Therapeutics
A number of institutional investors have recently made changes to their positions in the business. TD Asset Management Inc acquired a new stake in Rapport Therapeutics during the second quarter worth about $2,361,000. Johnson & Johnson acquired a new stake in Rapport Therapeutics in the 2nd quarter valued at $58,105,000. Sofinnova Investments Inc. bought a new stake in Rapport Therapeutics in the second quarter valued at $45,393,000. Davidson Kempner Capital Management LP acquired a new position in Rapport Therapeutics during the second quarter worth $229,000. Finally, ARCH Venture Management LLC bought a new position in shares of Rapport Therapeutics during the second quarter valued at $86,730,000.
Rapport Therapeutics Company Profile
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Read More
- Five stocks we like better than Rapport Therapeutics
- How Can Investors Benefit From After-Hours Trading
- Texas Roadhouse Stock Steering for New Highs This Year
- What Are Dividend Champions? How to Invest in the Champions
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- ETF Screener: Uses and Step-by-Step Guide
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.